Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short
Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...
Biogen Inc. (BIIB) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ETCompany ParticipantsTim Power - Head of IRChris Viehbacher ...
Seeking Alpha on MSN4h
Biogen targets $15.25-$16.25 EPS for 2025 amid LEQEMBI growth and cost savings
Biogen expects 2025 non-GAAP EPS of $15.25-$16.25 and a mid-single-digit decline in total revenue, primarily due to MS franchise pressures, including potential biosimilar and generic entries. Growth ...
Biogen details R&D cuts as it looks for more deals like HI-Bio acquisition
Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...
Benzinga.com2mon
Biogen (NASDAQ:BIIB) Stock Quotes, Forecast and News Summary
Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids ...
Nasdaq15d
March 2026 Options Now Available For Biogen (BIIB)
Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the March 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is ...